Literature DB >> 24435880

A small noncoding RNA signature found in exosomes of GBM patient serum as a diagnostic tool.

Lorea Manterola1, Elizabeth Guruceaga, Jaime Gállego Pérez-Larraya, Marisol González-Huarriz, Patricia Jauregui, Sonia Tejada, Ricardo Diez-Valle, Victor Segura, Nicolás Samprón, Cristina Barrena, Irune Ruiz, Amaia Agirre, Angel Ayuso, Javier Rodríguez, Alvaro González, Enric Xipell, Ander Matheu, Adolfo López de Munain, Teresa Tuñón, Idoya Zazpe, Jesús García-Foncillas, Sophie Paris, Jean Yves Delattre, Marta M Alonso.   

Abstract

BACKGROUND: Glioblastoma multiforme (GBM) is the most frequent malignant brain tumor in adults, and its prognosis remains dismal despite intensive research and therapeutic advances. Diagnostic biomarkers would be clinically meaningful to allow for early detection of the tumor and for those cases in which surgery is contraindicated or biopsy results are inconclusive. Recent findings show that GBM cells release microvesicles that contain a select subset of cellular proteins and RNA. The aim of this hypothesis-generating study was to assess the diagnostic potential of miRNAs found in microvesicles isolated from the serum of GBM patients.
METHODS: To control disease heterogeneity, we used patients with newly diagnosed GBM. In the discovery stage, PCR-based TaqMan Low Density Arrays followed by individual quantitative reverse transcriptase polymerase chain reaction were used to test the differences in the miRNA expression levels of serum microvesicles among 25 GBM patients and healthy controls paired by age and sex. The detected noncoding RNAs were then validated in another 50 GBM patients.
RESULTS: We found that the expression levels of 1 small noncoding RNA (RNU6-1) and 2 microRNAs (miR-320 and miR-574-3p) were significantly associated with a GBM diagnosis. In addition, RNU6-1 was consistently an independent predictor of a GBM diagnosis.
CONCLUSIONS: Altogether our results uncovered a small noncoding RNA signature in microvesicles isolated from GBM patient serum that could be used as a fast and reliable differential diagnostic biomarker.

Entities:  

Keywords:  GBM; biomarkers; diagnosis; exosomes; sncRNAs

Mesh:

Substances:

Year:  2014        PMID: 24435880      PMCID: PMC3956347          DOI: 10.1093/neuonc/not218

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  47 in total

1.  Part B--microRNAs: microRNA methods.

Authors:  Thomas D Schmittgen
Journal:  Methods       Date:  2008-01       Impact factor: 3.608

2.  A specific miRNA signature in the peripheral blood of glioblastoma patients.

Authors:  Patrick Roth; Jörg Wischhusen; Caroline Happold; P Anoop Chandran; Silvia Hofer; Günter Eisele; Michael Weller; Andreas Keller
Journal:  J Neurochem       Date:  2011-06-17       Impact factor: 5.372

Review 3.  Tumor-derived exosomes: a new source of tumor rejection antigens.

Authors:  F André; N E C Schartz; N Chaput; C Flament; G Raposo; S Amigorena; E Angevin; L Zitvogel
Journal:  Vaccine       Date:  2002-12-19       Impact factor: 3.641

4.  Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET.

Authors:  Héctor Peinado; Maša Alečković; Simon Lavotshkin; Irina Matei; Bruno Costa-Silva; Gema Moreno-Bueno; Marta Hergueta-Redondo; Caitlin Williams; Guillermo García-Santos; Cyrus Ghajar; Ayuko Nitadori-Hoshino; Caitlin Hoffman; Karen Badal; Benjamin A Garcia; Margaret K Callahan; Jianda Yuan; Vilma R Martins; Johan Skog; Rosandra N Kaplan; Mary S Brady; Jedd D Wolchok; Paul B Chapman; Yibin Kang; Jacqueline Bromberg; David Lyden
Journal:  Nat Med       Date:  2012-06       Impact factor: 53.440

5.  Fas ligand-positive membranous vesicles isolated from sera of patients with oral cancer induce apoptosis of activated T lymphocytes.

Authors:  Jeong Whun Kim; Eva Wieckowski; Douglas D Taylor; Torsten E Reichert; Simon Watkins; Theresa L Whiteside
Journal:  Clin Cancer Res       Date:  2005-02-01       Impact factor: 12.531

6.  Inhibition of U6 snRNA Transcription by PTEN.

Authors:  Stephanie Cabarcas; Kounosuke Watabe; Laura Schramm
Journal:  Online J Biol Sci       Date:  2010-09-30

7.  Extensive modulation of a set of microRNAs in primary glioblastoma.

Authors:  S A Ciafrè; S Galardi; A Mangiola; M Ferracin; C-G Liu; G Sabatino; M Negrini; G Maira; C M Croce; M G Farace
Journal:  Biochem Biophys Res Commun       Date:  2005-09-09       Impact factor: 3.575

8.  Diagnostic and prognostic microRNAs in stage II colon cancer.

Authors:  Troels Schepeler; Jørgen T Reinert; Marie S Ostenfeld; Lise L Christensen; Asli N Silahtaroglu; Lars Dyrskjøt; Carsten Wiuf; Frank J Sørensen; Mogens Kruhøffer; Søren Laurberg; Sakari Kauppinen; Torben F Ørntoft; Claus L Andersen
Journal:  Cancer Res       Date:  2008-08-01       Impact factor: 12.701

9.  Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells.

Authors:  Hadi Valadi; Karin Ekström; Apostolos Bossios; Margareta Sjöstrand; James J Lee; Jan O Lötvall
Journal:  Nat Cell Biol       Date:  2007-05-07       Impact factor: 28.824

10.  MiR-21 expression in the tumor cell compartment holds unfavorable prognostic value in gliomas.

Authors:  Simon Kjær Hermansen; Rikke Hedegaard Dahlrot; Boye Schnack Nielsen; Steinbjørn Hansen; Bjarne Winther Kristensen
Journal:  J Neurooncol       Date:  2012-10-28       Impact factor: 4.130

View more
  121 in total

Review 1.  Extracellular vesicles in breast cancer drug resistance and their clinical application.

Authors:  Shentong Yu; Yifang Wei; Yuqiao Xu; Yuan Zhang; Jipeng Li; Jian Zhang
Journal:  Tumour Biol       Date:  2016-01-21

Review 2.  The choice of endogenous controls in exosomal microRNA assessments from biofluids.

Authors:  G Occhipinti; M Giulietti; G Principato; F Piva
Journal:  Tumour Biol       Date:  2016-07-20

3.  Exosomes expressing the self-antigens myosin and vimentin play an important role in syngeneic cardiac transplant rejection induced by antibodies to cardiac myosin.

Authors:  Monal Sharma; Wei Liu; Sudhir Perincheri; Muthukumar Gunasekaran; T Mohanakumar
Journal:  Am J Transplant       Date:  2018-02-14       Impact factor: 8.086

4.  Immunomodulatory function of Treg-derived exosomes is impaired in patients with relapsing-remitting multiple sclerosis.

Authors:  Maryam Azimi; Mojdeh Ghabaee; Abdorreza Naser Moghadasi; Farshid Noorbakhsh; Maryam Izad
Journal:  Immunol Res       Date:  2018-08       Impact factor: 2.829

5.  Donor-Derived Exosomes With Lung Self-Antigens in Human Lung Allograft Rejection.

Authors:  M Gunasekaran; Z Xu; D K Nayak; M Sharma; R Hachem; R Walia; R M Bremner; M A Smith; T Mohanakumar
Journal:  Am J Transplant       Date:  2016-07-16       Impact factor: 8.086

6.  Circulating Serum Exosomal miRNAs As Potential Biomarkers for Esophageal Adenocarcinoma.

Authors:  Karen Chiam; Tingting Wang; David I Watson; George C Mayne; Tanya S Irvine; Tim Bright; Lorelle Smith; Imogen A White; Joanne M Bowen; Dorothy Keefe; Sarah K Thompson; Michael E Jones; Damian J Hussey
Journal:  J Gastrointest Surg       Date:  2015-05-06       Impact factor: 3.452

7.  MicroRNA expression signatures and their correlation with clinicopathological features in glioblastoma multiforme.

Authors:  Michael Henriksen; Kasper Bendix Johnsen; Pia Olesen; Linda Pilgaard; Meg Duroux
Journal:  Neuromolecular Med       Date:  2014-05-10       Impact factor: 3.843

Review 8.  Exosomal miRNAs in central nervous system diseases: biomarkers, pathological mediators, protective factors and therapeutic agents.

Authors:  Xiaohuan Xia; Yi Wang; Yunlong Huang; Han Zhang; Hongfang Lu; Jialin C Zheng
Journal:  Prog Neurobiol       Date:  2019-09-19       Impact factor: 11.685

Review 9.  The potential of tumor-derived exosomes for noninvasive cancer monitoring.

Authors:  Theresa L Whiteside
Journal:  Expert Rev Mol Diagn       Date:  2015-08-02       Impact factor: 5.225

10.  Exosomes isolated from plasma of glioma patients enrolled in a vaccination trial reflect antitumor immune activity and might predict survival.

Authors:  Laurent Muller; Sylvia Muller-Haegele; Masato Mitsuhashi; William Gooding; Hideho Okada; Theresa L Whiteside
Journal:  Oncoimmunology       Date:  2015-03-02       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.